Skip to main content
. 2020 Mar 19;37(5):2127–2143. doi: 10.1007/s12325-020-01276-3

Fig. 3.

Fig. 3

Baseline versus follow-up analysis of medications for CD-related symptoms or comorbid conditions. CD Crohn’s disease; UST ustekinumab. *There was a significant difference (p value < 0.05) between the pre- and post-index period use of anxiolytics, proton pump inhibitors, and anti-spasmodics